18 e-Letters

published between 2014 and 2017

  • Response

    We thank our colleagues for their interest in our study recently published in the Journal of Medical Genetics entitled ‘Risk assessment of maternally inherited SDHD paraganglioma and pheochromocytoma’.
    In response, we would like to underline that our study is a prospective study (see 'Methods' section) and not a case study.
    Today, the French national registry for hereditary paraganglioma (PGL.R) contains 193 SDHD different families carrying more than 60 different mutations, which is different from the Dutch situation where 87.1% of the SDHD-mutation carriers have the same founder Dutch mutation p.Asp92Tyr [1]. As explained in our paper, we have launched this prospective study because of the few cases of SDHD-tumors inherited via the maternal line reported in the literature, but also because we were aware of three other putative cases among patients suffering from paraganglioma or pheochromocytoma (PPGL) registered in PGL.R. Unfortunately, for those three cases we were not able to collect tumor tissues to definitely prove the role of the maternally inherited SDHD mutation in the tumorigenesis. The identification of a new case, a young asymptomatic woman, by our prospective study was nevertheless a surprise for us. So we strongly suggest our colleagues to take advantage from their large cohort of 600 at-risk subjects to perform the same prospective study in asymptomatic subjects, although most of them would carry the same SDHD founder mutation, to confi...

    Show More
  • Should we screen carriers of maternally inherited SDHD mutations?
    Jean-Pierre Bayley

    Dear Editor,

    We are writing to comment on a recent paper published in your journal by Burnichon and colleagues: Burnichon N, et al. Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma. J Med Genet. 2017; 54:125-133.

    In this paper a case study is presented describing development of pheochromocytoma in a carrier of an SDHD mutation. Although at first sight not an uncommon occu...

    Show More
  • Could a mutation in the hair keratin KRT83 cause recessive progressive symmetric erythrokeratoderma?
    Yuval Ramot

    Yuval Ramot1, Abraham Zlotogorski1, Maurice van Steensel2,3,4

    1 Department of Dermatology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel

    2 School of Medicine and School of Life Sciences, University of Dundee, United Kingdom

    3 Institute of Medical Biology, Singapore

    4 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

    In their rec...

    Show More
  • Re:NONO mutations and non compaction cardiomyopathy
    Daryl Armstrong Scott

    We only became aware of the paper by Reinstein et al. after our manuscript was published online. It is gratifying to know that we are not the only group who has identified left ventricular non-compaction (LVNC) in males with loss-of-function mutations in NONO.

    Conflict of Interest:

    None declared

  • NONO mutations and non compaction cardiomyopathy
    Eyal Reinstein

    The association has been described before but is not cited in the JMG manuscript

    Eur J Hum Genet. 2016 Jun 22. doi: 10.1038/ejhg.2016.72.

    Intellectual disability and non-compaction cardiomyopathy with a de novo NONO mutation identified by exome sequencing.

    Conflict of Interest:

    None declared

  • Re:A p.R464 H variation in the CCDC88C gene may not cause a dominant form of spinocerebellar ataxia
    Edwin Ho-Yin Chan

    To the Editor of Journal of Medical Genetics:

    Enabled by recent advances in sequencing technologies, genotypes from thousands of individuals are now available in online databases. While most of them aim to be the reference source of genotypes from healthy individuals, however, due to the lack of accompanying clinical data, geneticists now face the challenge of separating pathogenic mutations and rare polymorphisms. The fr...

    Show More
  • A p.R464 H variation in the CCDC88C gene may not cause a dominant form of spinocerebellar ataxia
    Yoshihisa Takiyama

    To the editor:

    The report that a novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia that appeared in your Journal (1) is of great interest. Although we identified the same heterozygous missense variation (c.1391G>A, p.R464H) as that reported (1) in a Japanese patient with autosomal dominant cerebellar ataxia (ADCA), we report here that this varia...

    Show More
  • Re:The putative role of Podxl in autosomal-recessive juvenile Parkinsonism
    B K. Thelma

    Response to e letter ID jmedgenet el; 2826 by Refaeli et al., dated June14, 2016 A considerable amount of literature on the role of podocalyxin-like (PODXL) protein in normal mammalian kidney functions and to a lesser extent in mouse brain development is available. We agree that these studies particularly, "Anuria, Omphalocele, and Perinatal Lethality in Mice Lacking the Cd34-Related Protein Podocalyxin" by Doyonnas et...

    Show More
  • The putative role of Podxl in autosomal-recessive juvenile Parkinsonism
    Kelly M McNagny


    Sudhaman, et al. Discovery of a frameshift mutation in podocalyxin- like (PODXL) gene, coding for a neural adhesion molecule, as causal for autosomal-recessive juvenile Parkinsonism. J Med Genet. 0:1-7, 2016.

    In the February 2016 edition of the Journal of Medical Genetics, Sudhaman et al(1) report the identification of a PODXL variant (c.89_90insGTCGCCCC) as the causative mutation in an Indian fam...

    Show More
  • Against all odds
    June Strada

    I just read the articles on SMA1, SMA2, SMA3. I felt it important to tell you of my son, born 1/26/70. When I took him to his first checkup at 3 months old, I voiced my concern for his floppy head. Again at 6 months old, when he couldn't sit up, roll over, kick against resistance. Finally, the Pediatrician agreed to get an appointment with Yale Hospital in CT at 8 mos. The biopsy was shown to be SMA 1. We weren't given...

    Show More